*On the primary endpoint of death, stroke, and rehospitalization at 1 year.
Clinical Study
25,000+
patients studied in Edwards clinical trials
Real world experience
450,000+
patients treated worldwide with Edwards TAVI valves
Data on file at Edwards Lifesciences.
Register for Updates
Thanks for signing up to receive Edwards Lifesciences newsletter!
References:
1.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019.
2.Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7).
3.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010.
4.Mack MJ, Leon MB, Thourani VH, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016.
5.Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.
Content relating to YourHigherStandard.com is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.